The Efficacy of Efgartigimod PH20 SC (VYVGART Hytrulo ) in Patients With Stiff Person Syndrome (SPS): A Double-blind, Placebo-controlled, Cross-over Trial

Stiff Person Syndrome (SPS) is a rare autoimmune disorder, characterized by: a) incapacitating diffuse muscle stiffness prominent in the axial, abdominal and thoracolumbar paraspinal muscles leading to hyperlordosis, difficulty turning and bending; b) painful muscle spasms precipitated by external stimuli with difficulty performing routine daily activities; and c) slow freezing gait with frequent falls and need for walking aids leading to disability. SPS is due to impaired inhibitory GABAergic neurotransmission associated with high-titer IgG antibodies against Glutamic Acid Decarboxylase (GAD), the rate-limiting enzyme for the synthesis of the inhibitory gammaaminobutyric acid (GABA). Although SPS patients respond to IVIg based on the PI's controlled study (NEJM 2001), several patients do not improve, or their response is modest and declines over time, as documented in a longitudinal study of 36 patients followed in our Jefferson clinic; because another controlled study we performed with Rituximab was negative and SPS is a progressive disease, new therapies are needed. Efgartigimod is an FcRn inhibitor that enhances the catabolism of circulating IgG; its subcutaneous, self-administered form, HYTRULO, has been effective and FDA-approved in patients with myasthenia gravis or CIDP poorly responding to IVIg. There is evidence that patients with myasthenia who also had SPS, Hytrulo not only helped their myasthenia but the SPS also impressively improved.
The present study is an investigator- initiated, double-blind, placebo controlled, cross-over, trial in 26 GAD-positive SPS patients poorly responding to available therapies. Patients will be recruited from the large number of patients seen and referred to the PI who is known for his work in SPS and has conducted the 2 previous controlled trials. Although Hytrulo is approved as selfadministered subcutaneous drug with pre-refilled syringes, in this study will be given by a contracted home infusion company once a week to ensure convenience, safety and validity. Patients will be randomized by the Jefferson Pharmacy to receiving Hytrulo or identical hyaluronidase-containing placebo for 3 months; then they will be crossed-over to placebo/Hytrulo for another 3 months. Efficacy will be based on one primary endpoint, the stiffness index, previously validated by the PI, and on two also validated secondary endpoints of time to walk and excitability index. This design provides the statistical power to objectively assess a 25-50% or greater change and objectively determine if Hytrulo offers meaningful benefits in reducing stiffness and spasms, improving gait and increasing quality of life in SPS patients poorly responding to current therapies.

Start Date30 Sep 2026

Sponsor / Collaborator

Thomas Jefferson University

NCT07760818

/ Not yet recruitingPhase 2

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants With Sjogren's Disease-Associated Sensorimotor or Sensory Polyneuropathy

This study aims to assess the efficacy and safety of efgartigimod PH20 in adults with Sjogren's Disease (SjD) associated with nerve damage. The study will assess how efgartigimod PH20 affects symptoms of SjD specifically linked to the peripheral nervous system; the safety and tolerability of efgartigimod PH20; and whether receiving efgartigimod PH20 affects the participant's quality of life.

Start Date14 Aug 2026

Sponsor / Collaborator

argenx SE

NCT07782775

/ CompletedPhase 1

A Phase 1, Open-Label, Randomized, Single-Dose, 2-Period Crossover, Bioequivalence Study of Efgartigimod PH20 SC Administered Via Autoinjector Versus Prefilled Syringe in Healthy Adult Participants

The aim of this study is to compare the amount of efgartigimod in the blood over time after it is injected via Prefilled syringe (PFS) and Autoinjector (AI).
The study will comprise 2 study periods of 3 weeks each. Each participant receives both efgartigimod PH20 SC AI and PFS treatments, in a different order.
Participants will be in the study for up to approximately 9 weeks.

Start Date19 Jun 2026

Sponsor / Collaborator

argenx SE

100 Clinical Results associated with Efgartigimod/Hyaluronidase

100 Translational Medicine associated with Efgartigimod/Hyaluronidase

100 Patents (Medical) associated with Efgartigimod/Hyaluronidase

Literatures (Medical) associated with Efgartigimod/Hyaluronidase

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Cost comparison of intravenous immunoglobulin and subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy

Article

Author: Kaisare, Vivek ; Yeh, Wei-Shi ; Muley, Suraj A. ; Myers, Leslie ; Wissmann, Christoph ; Gucciardi, Irene ; Bandy, Sarah

AIMS:

To compare the total treatment costs and cost per responder of IVIG and a newer therapy for adults with chronic inflammatory demyelinating polyneuropathy from a U.S. payer perspective.

METHODS:

A cost per responder analysis compared Vyvgart hytrulo with Panzyga administered at standard (1 g/kg) and higher (2 g/kg) maintenance doses over 6- and 12-month time horizons. Efficacy, safety data, and responder definitions were sourced from the ADHERE trial for Vyvgart hytrulo, and the ProCID trial for Panzyga. Total treatment costs included drug acquisition, administration, and costs by responder status reported in 2026 USD. Twelve-month Panzyga response rates incorporated published evidence and clinical guideline assumptions for responders, non-responders, and those with inadequate initial response requiring dose escalation. Deterministic scenario analyses evaluated reduced Panzyga effectiveness and hypothetical Vyvgart Hytrulo average sales price (ASP) discounts. Threshold analyses identified the efficacy reduction and ASP discount required to change the model conclusions. Probabilistic sensitivity analysis evaluated parameter uncertainty in the clinical response estimates.

RESULTS:

At 6 months, total treatment costs for Panzyga 1 g/kg, Panzyga 2 g/kg, and Vyvgart hytrulo were $124,812, $217,366, and $464,681, respectively. At 12 months, costs were $190,026, $402,301, and $698,583, respectively. Six-month responder rates were 80%, 92%, and 53% for Panzyga 1 g/kg, Panzyga 2 g/kg, and Vyvgart hytrulo, respectively; corresponding 12-month rates were 74%, 85%, and 48%. Cost-per-responder was consistently lower for Panzyga versus Vyvgart hytrulo at both time horizons. At 12 months, cost per responder was $256,792 for Panzyga 1 g/kg, $473,295 for Panzyga 2 g/kg, and $1,455,382 for Vyvgart hytrulo.

LIMITATIONS:

While no head-to-head clinical trial data were available, differences in trial design and responder definitions between studies may affect comparability.

CONCLUSIONS:

Under the assumptions of this model, Panzyga-based treatment pathways were associated with lower modeled total treatment costs and lower estimated cost per responder than Vyvgart hytrulo at both 6 and 12 months.

01 Oct 2026·Neurology and Therapy

Assessing Efgartigimod (VYVGART™) Social Media Posts in Generalized Myasthenia Gravis to Understand Patient, Caregiver, and Health Care Professional Sentiments

Article

Author: Bhattacharya, Kaushik ; Sharma, Anshul ; Hughes, Tom ; Batra, Aditya ; Shukla, Swati ; Jarmale, Shreyas ; Whangbo, Albert

INTRODUCTION:

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness (ocular, bulbar, limb, and respiratory). Efgartigimod (VYVGART), a first-in-class neonatal Fc receptor antagonist, was approved for treatment of generalized MG (gMG). This study aimed to explore real-world sentiments, wherein in sentiments refer to real-world perceptions expressed by patients, caregivers, and healthcare professionals (HCPs) on VYVGART and VYVGART Hytrulo, through structured social media analysis.

METHODS:

This social media listening study was designed to collect posts mentioning VYVGART and VYVGART Hytrulo for gMG using predefined keywords from social media platforms across the globe. Organic English-language posts from several platforms, such as Reddit, X (formerly Twitter), Facebook, Forums, Review, and Tumblr etc., were analyzed for the timeframe August 1, 2021 to September 30, 2024. Posts were categorized into themes, namely "brand awareness," "treatment access," "treatment experience," and "treatment support."

RESULTS:

A total of 1046 posts (USA 9%, Europe 6%, Unknown 85%) contained relevant information; 1015 posts were related to VYVGART and 55 posts were related to VYVGART Hytrulo. Most posts focused on treatment experience (593 posts) and brand awareness (402 posts). Overall sentiments towards VYVGART and VYVGART Hytrulo were positive in 49%, 30%, and 20% of patient, caregiver, and HCP posts, respectively. Patient posts expressed optimism about initiating treatment. There were fewer caregiver and HCP discussions and these were predominantly neutral.

CONCLUSION:

These findings suggest positive real-world perceptions of VYVGART and VYVGART Hytrulo among patients in improving symptoms and health-related quality of life.

01 Sep 2026·JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

Long‐Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE / ADHERE + Trial Interim Analysis

Article

Author: Querol, Luis ; Istas, Geoffrey ; Lewis, Richard A. ; Mole, Trevor ; Rinaldi, Simon ; Van Hoorick, Benjamin ; Kuwabara, Satoshi ; Allen, Jeffrey A. ; Stettner, Mark

ABSTRACT:

Background and Aims:

In ADHERE, subcutaneous efgartigimod PH20 (1000 mg once weekly) was effective and well tolerated in participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). ADHERE+ is an open‐label extension of ADHERE assessing long‐term safety and efficacy.

Methods:

Eligible participants from ADHERE run‐in period (prior CIDP treatments discontinued), stage A (open‐label efgartigimod), and stage B (stage A responders randomized to placebo or efgartigimod) could roll over to ADHERE+ and receive efgartigimod. The primary outcome was to assess long‐term safety and tolerability. Efficacy outcomes evaluated adjusted Inflammatory Neuropathy Cause and Treatment (aINCAT) score, Inflammatory Rasch‐built Overall Disability Scale (I‐RODS) score, and mean grip strength (GS) from ADHERE run‐in baseline through ADHERE+ week 36.

Results:

At interim data cut‐off (February 16, 2024), 228/229 eligible participants advanced to ADHERE+. Prolonged efgartigimod exposure did not increase the incidence ( n = 171/228 [75.0%]) or severity of TEAEs (grade ≥ 3 TEAEs, n = 41/228 [18.0%]); regardless of immunoglobulin G level, there was a low incidence of infections. Stage A responders reported long‐term clinically meaningful improvements in mean aINCAT (decreased by 1.2 points), I‐RODS centile metric (increase of 8.8 points), and GS scores (increase of 17.5 kPa) from run‐in baseline to ADHERE+ week 36, irrespective of stage B treatment.

Interpretation:

Interim results from ADHERE+ indicate long‐term efgartigimod PH20 treatment in participants with CIDP was well tolerated (maximum exposure = 187.3 weeks; mean (SD) treatment duration = 58.0 [33.8] weeks). Clinically meaningful improvements in disability and strength were observed across assessments, regardless of stage B treatment or prior treatment status, with greater improvements seen over time.

148

News (Medical) associated with Efgartigimod/Hyaluronidase

12 Oct 2026

·www.globenewswire.com

argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease

October 8, 2026, Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren's disease. The decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the study for futility following an interim analysis. The IDMC concluded that the UNITY study is unable to meet its primary endpoint. Safety was consistent with efgartigimod's established profile and no new safety signals were identified. "We are disappointed by this outcome, most of all for people living with Sjögren's disease, who are still waiting for treatments that fundamentally change the course of their disease," said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx. "Sjögren's Disease is one of the most heterogeneous and complicated diseases in immunology, and unraveling the biology of complex diseases is at the heart of what we do. We will analyze these data in depth and share what we learn with the Sjögren's community. We are grateful to the patients, families, investigators and site staff who made this study possible." Following study close and database lock, argenx will conduct a comprehensive analysis of the data to understand the study's outcome and generate insights that may inform future research in Sjögren's disease. UNITY is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study with an open-label extension, designed to evaluate the efficacy, safety and tolerability of efgartigimod SC in adults with moderate-to-severe Sjögren's disease. To be eligible, patients had to meet the 2016 ACR/EULAR classification criteria for primary Sjögren's disease, test positive for anti-Ro/SSA autoantibodies and have moderate-to-severe systemic disease activity (clinESSDAI ≥6) while receiving stable background standard of care. Patients were randomized 1:1 to receive weekly efgartigimod SC or placebo during the double-blind treatment period. The primary endpoint was change from baseline in systemic disease activity, as measured by the clinical EULAR Sjögren's Syndrome Disease Activity Index (clinESSDAI), at Week 48. Key secondary endpoints included the proportion of patients achieving low disease activity (clinESSDAI <5), responder status on the Sjögren's Tool for Assessing Response (STAR), change in patient-reported symptoms as measured by the Diary of Sjögren's Symptoms Assessment (DiSSA), and safety and tolerability. Sjögren's disease is a chronic, slowly progressive, inflammatory systemic autoimmune disease characterized by immune-mediated destruction of the exocrine glands. It can be severely debilitating and have a negative impact on patient quality of life, with commonly reported symptoms including dry eyes and mouth, fatigue and joint pain. In addition, a substantial subset of patients suffer from extraglandular systemic disease. While the presence of anti-Ro and IgG autoantibodies is considered a hallmark of the disease, its underlying cause is believed to be multifactorial, with environmental triggers leading to autoimmunity and chronic inflammation. The disease predominantly affects women, with a 9:1 female-to-male incidence ratio. Given its heterogeneous nature, the treatment journey can be challenging, with long delays and high rates of misdiagnosis. VYVGART® (efgartigimod alfa fcab) is a first-in-class human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies. VYVGART Hytrulo® is a subcutaneous combination of efgartigimod alfa (VYVGART) and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology to facilitate subcutaneous injection delivery of biologics. VYVGART is approved for generalized myasthenia gravis (gMG) and immune thrombocytopenia (Japan only). VYVGART Hytrulo is approved for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo may be marketed under different proprietary names in other regions. argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. The content above comes from the network. if any infringement, please contact us to modify.

Drug ApprovalClinical ResultImmunotherapy

08 Oct 2026

·firstwordpharma.com

argenx ends Vyvgart's late-stage study in Sjögren’s disease over futility

argenx said Thursday that it will end the Sjögren's disease programme for the subcutaneous (SC) version of its human IgG1 antibody fragment Vyvgart (efgartigimod alfa), after an Independent Data Monitoring Committee (IDMC) recommended stopping a Phase III trial for futility. The news sent the company's shares down nearly 18%. The UNITY study enrolled 631 patients who met the criteria for primary Sjögren's disease, were anti-Ro/SSA-positive and had moderate-to-severe systemic disease activity despite stable standard of care. Participants were randomised to weekly subcutaneous Vyvgart or placebo. The primary endpoint was change from baseline in Clinical European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (clinESSDAI) score at week 48.Following an interim analysis, the IDMC concluded that UNITY was unlikely to meet its primary efficacy goal — thus marking the second such setback for the drug, after an earlier trial in thyroid eye disease was stopped due to futility. The company, however, noted there weren't any safety concerns in the Sjögren's study, with no new signals identified."We are disappointed by this outcome, most of all for people living with Sjögren's disease, who are still waiting for treatments that fundamentally change the course of their disease," said Luc Truyen, chief medical officer at argenx.Vyvgart was first approved by the FDA in 2021 as an intravenous infusion for generalised myasthenia gravis (gMG). The SC formulation — which combines efgartigimod alfa with hyaluronidase under the name Vyvgart Hytrulo — was authorised for gMG in 2023 and cleared for chronic inflammatory demyelinating polyneuropathy a year later. The 'pipeline-in-a-product' also remains under investigation for multiple IgG-mediated autoimmune conditions, recently delivering success in a Phase III trial in adults with autoimmune myositis.

Phase 3Drug ApprovalClinical Result

08 Oct 2026

·www.biospace.com

Argenx shutters Sjogren’s study, losing blockbuster expansion opportunity for Vyvgart

iStock, Arsgera Argenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Biosciences buy. Argenx is discontinuing a late-stage study of Vyvgart Hytrulo in Sjogren’s disease due to futility, a surprise setback that removes “the next potential blockbuster expansion opportunity” for the drug, William Blair analysts wrote on Thursday. The biopharma is ending its Phase 3 UNITY trial after an independent data committee determined that the study would not meet its primary endpoint of improving systemic disease activity, according to a Thursday release . As of market open, argenx’s stock had tumbled nearly 14%, or about $130 per share, resting at around $797 as of 11 a.m. ET. UNITY had been evaluating argenx’s Vyvgart Hytrulo injection for Sjogren’s, an autoimmune disorder that most often affects moisture glands, with the most common symptoms of dry eyes and dry mouth. Vyvgart Hytrulo is currently approved to treat generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy and recently scored a late-stage win in autoimmune myositis, a group of rare diseases that cause the immune system to attack the muscles. Today’s futility announcement is surprising given that the trial results weren’t expected until the second half of 2027, William Blair wrote in a Thursday note. Argenx told the firm that the futility analysis included data from more than 500 patients—as compared to the 630 enrolled—indicating that the review may have been conducted earlier than the primary endpoint assessment expected at week 48. “Sjogren’s disease drug development has been bogged down by high placebo response rates, making it difficult to achieve robust separation versus placebo,” according to William Blair. In argenx’s Phase 2 RHO study , the asset appeared differentiated in Sjogren’s compared to placebo at week 24. However, the study was underpowered and there was no difference compared to placebo in percentage of patients achieving at least a three-point improvement on an industry scale measuring disease activity, William Blair wrote. The analysts had previously estimated peak sales of $1.4 billion in Sjogren’s but noted competition in the space, specifically from Novartis’ investigational monoclonal antibody ianalumab and Amgen’s CD40L antagonist fusion protein dazodalibep , both of which have recorded Phase 3 wins. Mergers & acquisitions Argenx deepens immuno expertise with $2.2B Forte Biosciences buy The star of the takeover is Forte Biosciences’ investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease. July 27, 2026 · 2 min read · Tristan Manalac Read more Meanwhile, argenx announced a mid-stage celiac disease win in a separate release . The Phase 2 trial evaluated the biotech’s investigational CD122 inhibitor FB102, which it picked up from Forte Biosciences in a $2.2 billion acquisition this summer. Patients receiving FB102 demonstrated a statistically significant change from baseline in a health measure of the small intestine, meeting the study’s primary endpoint. Given the findings, which argenx heralded as the “first Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease,” the biopharma plans to move the asset into late-stage development. The celiac disease plans expand argenx’s late-stage pipeline ahead of the closely-watched Phase 3 findings expected soon for monoclonal antibody empasiprubart in multifocal motor neuropathy.

Phase 2Drug ApprovalPhase 3Clinical ResultAcquisition

100 Deals associated with Efgartigimod/Hyaluronidase

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	United States	argenx SE	21 Jun 2024
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	United States	argenx BV	21 Jun 2024
Myasthenia Gravis	United States	argenx BV	20 Jun 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Graves Disease	Phase 3	United States	argenx SE	10 Jun 2026
Graves Disease	Phase 3	Japan	argenx SE	10 Jun 2026
Graves Disease	Phase 3	Belgium	argenx SE	10 Jun 2026
Graves Disease	Phase 3	Bulgaria	argenx SE	10 Jun 2026
Graves Disease	Phase 3	Canada	argenx SE	10 Jun 2026
Graves Disease	Phase 3	Denmark	argenx SE	10 Jun 2026
Graves Disease	Phase 3	Germany	argenx SE	10 Jun 2026
Graves Disease	Phase 3	Latvia	argenx SE	10 Jun 2026
Graves Disease	Phase 3	Lithuania	argenx SE	10 Jun 2026
Graves Disease	Phase 3	Poland	argenx SE	10 Jun 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05523167 (ALKIVIA, ACR2026)	Phase 2/3	Idiopathic Inflammatory Myopathies	89	Efgartigimod PH20 SC	fdvjouvmqw(gepbiftggm) = Mean total IgG levels decreased by 66.2% at the first sampling timepoint (Week 4), which was maintained throughout the trial until Week 24 (60.3%-70.1%). No substantial changes in IgG levels were noted in the PBO group. nfltjiunkp (qqbfjrlvdy )	Positive	06 Nov 2026
				Placebo
NCT04818671 (ADAPT-SC+, Pubmed \| Front Neurol)	Phase 3	Myasthenia Gravis	180	Efgartigimod PH20 SC 1000 mg	musbepgwae(zmlvwcufvx) = ijrryfppag hnxepkcgpa (fuzmpcrvyk ) View more	Positive	21 Aug 2026
NCT05523167 (ALKIVIA, EULAR2026)	Phase 2/3	Idiopathic Inflammatory Myopathies	89	EFGARTIGIMOD PH20 SC	iflcmkpoox(fxnivzpisn) = cuezqzzhvl ekncgoghlr (kwqyoqusim ) View more	Positive	11 Jun 2026
				Placebo rHuPH20 SC	iflcmkpoox(fxnivzpisn) = bxxhvjbzgg ekncgoghlr (kwqyoqusim ) View more
NCT04281472 (ADHERE, AAN2026)	Phase 2	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	5	Efgartigimod PH20 SC (Chronic Inflammatory Demyelinating Polyradiculoneuropathy + newly diagnosed + treatment-naïve)	rdetvugkal(emszhldbef) = Most common side effects were injection site reaction, urticaria and rash which resolved with repeated injections. osvczdmscy (khvugslwxa )	Positive	25 Apr 2026
NCT04281472 (ADHERE, MDA2026)	Phase 2	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	221	Efgartigimod PH20 SC 1000 mg	xiqpwrsltb(oijbfxqisu) = gflfpshoni buwqetmhzc (dswbsdnjxj ) View more	Positive	08 Mar 2026
				Placebo	xiqpwrsltb(oijbfxqisu) = gphdumsnbv buwqetmhzc (dswbsdnjxj ) View more
NCT05523167 (ALKIVIA, MDA2026)	Phase 2/3	Idiopathic Inflammatory Myopathies	89	Efgartigimod PH20 SC	cybuatozrp(ezjbvkcllw) = bpeozoskzy idntoalkri (qvrurenomc )	Positive	08 Mar 2026
				Placebo	cybuatozrp(ezjbvkcllw) = tozzgrfvxk idntoalkri (qvrurenomc )
NCT04280718 (ADHERE+, MDA2026)	Phase 2	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	229	Efgartigimod PH20 SC 1000 mg	oafzuzqisg(gersztqopy) = xylhwtubkm cqfucbvbsr (ajsyvvhnme ) View more	Positive	08 Mar 2026
NCT04818671 (ADAPTSC+ \| ADAPT-SC+, CTgov)	Phase 3	Myasthenia Gravis	184	efgartigimod PH20 SC	ymtczhmksi = qlhswzqubj yjkxyorsqf (srxmldmvpq, jrixwlfeei - heqrhyqmqo) View more	-	22 Jan 2026
NCT05523167 (ALKIVIA, ACR2025)	Phase 2/3	Idiopathic Inflammatory Myopathies	89	Efgartigimod PH20 SC plus standard of care (SOC)	uikddxzasg(gylefzkbvz) = pjikvwuges ieheiilbml (nokffmmlee ) View more	Positive	24 Oct 2025
				Placebo PH20 (PBO) plus SOC	uikddxzasg(gylefzkbvz) = gysjsgtpgj ieheiilbml (nokffmmlee ) View more
NCT05267600 (BALLAD, CTgov)	Phase 2/3	Pemphigoid, Bullous	98	Prednisone+efgartigimod PH20 SC (Efgartigimod PH20 SC)	poyolzdiuk = uihgkxrpst houytieezc (luvtkhqrsr, mbfzhmoqdl - ctcuvrakux) View more	-	23 Oct 2025
				placebo+Prednisone (Placebo PH20 SC)	poyolzdiuk = dzfrkordos houytieezc (luvtkhqrsr, qslktrwyrx - laihegodwe) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis